Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Breast Cancer (Locally Advanced or Metastatic) · HER2-positive Breast Cancer · Triple-Negative Breast Cancer (TNBC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Contact: Study coordinator (Zhen J Peng, Phd) · Zhen-Peng@beijing-biotech.com · +8613076790039

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE2

Beijing, China

GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors

Head and Neck Cancer · Malignant Melanoma · Colorectal Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Goyang-si, South Korea · Seoul, South Korea

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor

Abroad (travel likely)RecruitingPHASE3

Gilbert, United States · Beverly Hills, United States

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer

Breast Cancer

Abroad (travel likely)RecruitingPHASE1

Grand Rapids, United States · San Antonio, United States